<DOC>
	<DOCNO>NCT02596373</DOCNO>
	<brief_summary>The hypothesis clinical research study discover study drug Mitoxantrone Hydrochloride Liposome Injection shrink slow growth advance recurrent metastatic breast cancer</brief_summary>
	<brief_title>A Study Mitoxantrone Hydrochloride Liposome Injection Advanced Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description>Mitoxantrone Hydrochloride Liposome Injection kind anthraquinone compound , antineoplastic effect view preclinical test . The investigator 's phase Ⅰstudy show drug 's toxicity manageable tolerable 20 mg/m2 . The hypothesis clinical research study discover study drug Mitoxantrone Hydrochloride Liposome Injection shrink slow growth advance recurrent metastatic breast cancer . The safety Mitoxantrone Hydrochloride Liposome Injection also study . Patients physical state , symptom , change size tumor , laboratory finding obtain on-study help research team decide Mitoxantrone Hydrochloride Liposome Injection safe effective advanced recurrent metastatic breast cancer patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Written inform consent prior study specific screening procedure ; ≥ 18 ≤ 75 year age , female ; Advanced recurrent Metastatic breast cancer , comfirmed histological analysis and/or cytology analysis . Have fail least two chemotherapy regimen aim advanced recurrent metastatic focus ; Adapted receive chemotherapy ; Women diagnose human epidermal growth factor receptor negative ( HER2 ) ; Women diagnose HER2+ , unable treat AntiHER2+ target therapy . HER2 define 0 1+ stain immunohistochemistry FISH negative gene amplification . HER2+ define +++ stain immunohistochemistry FISH positive gene amplification ; Not suitable endocrine theapy tolerance endocrine therapy ; Have least one measurable site disease accord RECIST1.1 criterion ; If chemotherapy regimens contain anthracyclinebased drug , duration palindromia chemotherapy regimens less 12 mounths ; ECOG performance status 02 , life expectancy 3 mounths ; Cardiac function almost normal ( NYHA classification Grade 1 , LVEF≥ 50％ ) ; Sexually active woman childbearing potential must use medically acceptable form contraception ; Adequate hepatic , renal hematologic function : leukocyte≥3.0×10^9/L , neutrophils≥1.5×10^9/L , platelets≥75×10^9/L , hemoglobin≥90g/L , serum bilirubin≤1.5×ULN , ALT≤2.5×ULN ( 5×for liver metastasis ) , AST≤2.5×ULN ( 5×for liver metastasis ) , creatinine clearance rate≤1.5×ULN ; Suffering serious internal disease , include serious heart attack , cerebrovascular disease , uncontrolled diabetes , uncontrolled hypertension , uncontrolled infection , active peptic ulcer ; Uncontrolled brain metastasis ; Pregnant lactate woman ; Mitoxantrone use ; Anthracyclinebased drug use relapse metastasis ; The cumulative dos doxorubicin epirubicin inclusion surpass 360 mg/m2 600 mg/m2 , respectively ; Less 4 week last chemotherapy , less 4 week last radiotherapy , less 2 week last endocrinotherapy ; Other antineoplastic drug need use study ; History anthracyclinebased drug allergy ; History liposome drug allergy ; Uncontrolled psychosis uncontrolled infection disease ; Unsuited participate thsi study judge investigator ;</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>